儿童神经纤维瘤病1型颅内肿瘤性病变的治疗进展

doi:10.3969/j.issn.1674-8115.2024.03.014

上海交通大学学报（医学版） ›› 2024, Vol. 44 ›› Issue (3): 399-406.doi: 10.3969/j.issn.1674-8115.2024.03.014

• 综述 • 上一篇

儿童神经纤维瘤病1型颅内肿瘤性病变的治疗进展

刘美伶¹(), 周亚兵², 王晓强¹()

^1.上海交通大学医学院附属新华医院儿神经外科，上海 200092
^2.上海交通大学医学院附属新华医院中医科，上海 200092

收稿日期:2023-11-13 接受日期:2024-01-11 出版日期:2024-03-28 发布日期:2024-04-29
通讯作者: 王晓强 E-mail:lmling_123@126.com;wangxiaoqiang419@163.com
作者简介:刘美伶（1999—），女，硕士生；电子信箱：lmling_123@126.com。
基金资助:
上海市“科技创新行动计划”医学创新研究专项(20Y21900500)

Advances in the treatment of intracranial neoplastic lesions in children with neurofibromatosis 1

LIU Meiling¹(), ZHOU Yabing², WANG Xiaoqiang¹()

^1.Department of Pediatric Neurosurgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
^2.Department of Traditional Chinese Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received:2023-11-13 Accepted:2024-01-11 Online:2024-03-28 Published:2024-04-29
Contact: WANG Xiaoqiang E-mail:lmling_123@126.com;wangxiaoqiang419@163.com
Supported by:
Shanghai Science and Technology Innovation Action Plan for Medical Research(20Y21900500)

摘要/Abstract

摘要：

神经纤维瘤病1型（neurofibromatosis 1，NF1）好发于儿童，是神经系统最常见的常染色体显性遗传病之一，是基因缺陷使神经嵴细胞发育异常导致的多系统损害。NF1的外显率几乎是100%，主要临床特征为皮肤牛奶咖啡斑和周围神经多发神经纤维瘤。NF1在颅内能引起肿瘤性病变，后者按照病理学依据可分为低级别肿瘤、高级别肿瘤和类似肿瘤病变。合并NF1的颅内肿瘤多为低级别肿瘤，视路胶质瘤最为多见，其次是脑干胶质瘤，其余部位和类型的肿瘤也有所发生；高级别肿瘤并不常见。而类似肿瘤病变即不明明亮物体虽不是肿瘤，但却是NF1儿童最常见的具有部分肿瘤性质的颅内异常病变。这些肿瘤性病变可通过观察、手术、化学治疗、放射治疗、靶向治疗等方式处理，不同病变的最佳处理方式不同，其预后也有所不同。目前针对儿童NF1颅内肿瘤性病变的治疗方式还有所争议。该文就此种病变的特点和治疗进展进行阐述，旨在提高大众对NF1肿瘤性病变的认知水平，提供针对性的诊疗方案，推进NF1患者完善神经外科治疗。

关键词: 神经纤维瘤病1型, 颅内肿瘤性病变, 儿童, 治疗

Abstract:

Neurofibromatosis 1 (NF1) is one of the most common autosomal dominant genetic diseases of the nervous system, which occurs predominantly in children. It is a multi-system damage caused by genetic defects that cause abnormal development of neural crest cells. The penetrance of NF1 is almost 100%, and the main clinical features are cafe-au-lait spots on the skin and multiple neurofibromas in peripheral nerves. NF1 can lead to intracranial neoplastic lesions, which can be divided into low grade tumors, high grade tumors and tumor-like lesions according to pathology. Most intracranial tumors with NF1 are low grade tumors, and optic pathway gliomas are the most universal, followed by brainstem gliomas, but other types of low grade tumors can also occur on other sites. High grade tumors are uncommon. Although tumor-like lesions/ unidentified bright objects are not tumors, they are the most widespread intracranial abnormalities with partial tumor nature in NF1 children. These neoplastic lesions can be treated by observation, surgery, chemotherapy, radiotherapy, targeted therapy, etc. The best treatment for different lesions is different, and their prognosis is also distinct. At present, the treatment of intracranial neoplastic lesions of NF1 in children is still controversial. This article reviews the characteristics and treatment progress of this disease, aiming to improve the public′s awareness of NF1 neoplastic lesions, provide professional plans of diagnosis and treatment, and finally promote the perfect neurosurgical therapy of NF1 patients.

Key words: neurofibromatosis 1 (NF1), intracranial neoplastic lesion, children, treatment

中图分类号:

R739.41

刘美伶, 周亚兵, 王晓强. 儿童神经纤维瘤病1型颅内肿瘤性病变的治疗进展[J]. 上海交通大学学报（医学版）, 2024, 44(3): 399-406.

LIU Meiling, ZHOU Yabing, WANG Xiaoqiang. Advances in the treatment of intracranial neoplastic lesions in children with neurofibromatosis 1[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 399-406.

参考文献 48

1	KRESAK J L, WALSH M. Neurofibromatosis: a review of NF1, NF2, and schwannomatosis[J]. J Pediatr Genet, 2016, 5(2): 98-104.
2	GUTMANN D H, FERNER R E, LISTERNICK R H, et al. Neurofibromatosis type 1[J]. Nat Rev Dis Primers, 2017, 3: 17004.
3	NIX J S, BLAKELEY J, RODRIGUEZ F J. An update on the central nervous system manifestations of neurofibromatosis type 1[J]. Acta Neuropathol, 2020, 139(4): 625-641.
4	FARAZDAGHI M K, KATOWITZ W R, AVERY R A. Current treatment of optic nerve gliomas[J]. Curr Opin Ophthalmol, 2019, 30(5): 356-363.
5	DAL BELLO S, MARTINUZZI D, TERESHKO Y, et al. The present and future of optic pathway glioma therapy[J]. Cells, 2023, 12(19): 2380.
6	SHAMJI M F, BENOIT B G. Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications[J]. Neurosurg Focus, 2007, 23(5): E3.
7	TAYLOR T, JASPAN T, MILANO G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system[J]. Br J Radiol, 2008, 81(970): 761-766.
8	KELLY J P, WEISS A H. Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1[J]. Neuro-oncology, 2013, 15(11): 1560-1567.
9	PACKER R J, ATER J, ALLEN J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas[J]. J Neurosurg, 1997, 86(5): 747-754.
10	FUSS M, HUG E B, SCHAEFER R A, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique[J]. Int J Radiat Oncol Biol Phys, 1999, 45(5): 1117-1126.
11	周勇, 赵曜. 视神经胶质瘤的诊断与治疗[J]. 河北医学, 2003, 9(3): 248-250.
	ZHOU Y, ZHAO Y. Diagnosis and treatment of the optic nerve glioma [J]. Hebei Medicine, 2003, 9(3): 248-250.
12	COONEY T, YEO K K, KLINE C, et al. Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma[J]. Neurooncol Pract, 2020, 7(1): 4-10.
13	GUO Y J, PAN W W, LIU S B, et al. ERK/MAPK signalling pathway and tumorigenesis[J]. Exp Ther Med, 2020, 19(3): 1997-2007.
14	FANGUSARO J, ONAR-THOMAS A, POUSSAINT T Y, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial[J]. Lancet Oncol, 2019, 20(7): 1011-1022.
15	YAMASAKI F, TAKANO M, YONEZAWA U, et al. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review[J]. Childs Nerv Syst, 2020, 36(3): 635-639.
16	HUA H, KONG Q B, ZHANG H Y, et al. Targeting mTOR for cancer therapy[J]. J Hematol Oncol, 2019, 12(1): 71.
17	WILSON B N, JOHN A M, HANDLER M Z, et al. Neurofibromatosis type 1: new developments in genetics and treatment[J]. J Am Acad Dermatol, 2021, 84(6): 1667-1676.
18	COSTA A A, GUTMANN D H. Brain tumors in neurofibromatosis type 1[J]. Neurooncol Adv, 2019, 1(1): vdz040.
19	GUILLAMO J S, CRÉANGE A, KALIFA C, et al. Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1): a retrospective study of 104 patients[J]. Brain, 2003, 126(Pt 1): 152-160.
20	BILANIUK L T, MOLLOY P T, ZIMMERMAN R A, et al. Neurofibromatosis type 1: brain stem tumours[J]. Neuroradiology, 1997, 39(9): 642-653.
21	LIU Z Y, FENG S S, LI J, et al. The survival benefits of surgical resection and adjuvant therapy for patients with brainstem glioma[J]. Front Oncol, 2021, 11: 566972.
22	GAGLIARDI F, DE DOMENICO P, SNIDER S, et al. γ knife radiosurgery as primary treatment of low-grade brainstem gliomas: a systematic review and metanalysis of current evidence and predictive factors[J]. Crit Rev Oncol Hematol, 2021, 168: 103508.
23	BYRNE S, CONNOR S, LASCELLES K, et al. Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas[J]. J Neurooncol, 2017, 133(3): 609-614.
24	Pascual-Castroviejo I, Pascual-Pascual S I, Viaño J, et al. Posterior fossa tumors in children with neurofibromatosis type 1 (NF1)[J]. Childs Nerv Syst, 2010, 26(11): 1599-1603.
25	SAIT S F, GIANTINI-LARSEN A M, TRINGALE K R, et al. Treatment of pediatric low-grade gliomas[J]. Curr Neurol Neurosci Rep, 2023, 23(4): 185-199.
26	WISOFF J H, SANFORD R A, HEIER L A, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children′s Oncology Group[J]. Neurosurgery, 2011, 68(6): 1548-1554;discussion 1554-1555.
27	SIEVERT A J, FISHER M J. Pediatric low-grade gliomas[J]. J Child Neurol, 2009, 24(11): 1397-1408.
28	FISHER B J, BAUMAN G S, LEIGHTON C E, et al. Low-grade gliomas in children: tumor volume response to radiation[J]. Neurosurg Focus, 1998, 4(4): e5.
29	WANG T J C, MEHTA M P. Low-grade glioma radiotherapy treatment and trials[J]. Neurosurg Clin N Am, 2019, 30(1): 111-118.
30	CAMPAGNE O, YEO K K, FANGUSARO J, et al. Clinical pharmacokinetics and pharmacodynamics of selumetinib[J]. Clin Pharmacokinet, 2021, 60(3): 283-303.
31	FISHER M J, BLAKELEY J O, WEISS B D, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas[J]. Neuro-oncology, 2022, 24(11): 1827-1844.
32	FRIEDRICH R E, MODEMANN M. Neurofibromatosis type 1-associated plexiform neurofibromas of the face and adjacent head regions: topography of lesions and surgical treatment data of 179 patients[J]. J Maxillofac Oral Surg, 2023, 22(3): 511-524.
33	NGUYEN R, KLUWE L, FUENSTERER C, et al. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits[J]. J Pediatr, 2011, 159(4): 652-655.e2.
34	NEEDLE M N, CNAAN A, DATTILO J, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children′s Hospital of Philadelphia experience, 1974-1994[J]. J Pediatr, 1997, 131(5): 678-682.
35	AVERY R A, KATOWITZ J A, FISHER M J, et al. Orbital/periorbital plexiform neurofibromas in children with neurofibromatosis type 1: multidisciplinary recommendations for care[J]. Ophthalmology, 2017, 124(1): 123-132.
36	GROSS A M, WOLTERS P L, DOMBI E, et al. Selumetinib in children with inoperable plexiform neurofibromas[J]. N Engl J Med, 2020, 382(15): 1430-1442.
37	李帮涛, 张格, 庞启明, 等. 司美替尼治疗儿童1型神经纤维瘤病1例[J]. 中华儿科杂志, 2023, 61(10): 938-940.
	LI B T, ZHANG G, PANG Q M, et al. Selumetinib in the treatment of type 1 neurofibromatosis in a child [J]. Chinese Journal of Pediatrics, 2023, 61(10): 938-940.
38	WIMMER K, ROSENBAUM T, MESSIAEN L. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1[J]. Clin Genet, 2017, 91(4): 507-519.
39	RANALLI M, BONI A, CAROLEO A M, et al. Molecular characterization of medulloblastoma in a patient with neurofibromatosis type 1: case report and literature review[J]. Diagnostics, 2021, 11(4): 647.
40	MARTINEZ-VELEZ N, MARIGIL M, GARCÍA-MOURE M, et al. δ-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models[J]. Acta Neuropathol Commun, 2019, 7(1): 64.
41	POLLACK I F, AGNIHOTRI S, BRONISCER A. Childhood brain tumors: current management, biological insights, and future directions[J]. J Neurosurg Pediatr, 2019, 23(3): 261-273.
42	POLLACK I F, BOYETT J M, YATES A J, et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience[J]. Neuro Oncol, 2003, 5(3): 197-207.
43	FRIEDMAN G K, JOHNSTON J M, BAG A K, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas[J]. N Engl J Med, 2021, 384(17): 1613-1622.
44	WANG L M, ENGLANDER Z K, MILLER M L, et al. Malignant glioma[J]. Adv Exp Med Biol, 2023, 1405: 1-30.
45	DIMARIO F J Jr, RAMSBY G, GREENSTEIN R, et al. Neurofibromatosis type 1: magnetic resonance imaging findings[J]. J Child Neurol, 1993, 8(1): 32-39.
46	LOPES FERRAZ FILHO J R, MUNIS M P, SOARES SOUZA A, et al. Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1[J]. Pediatr Radiol, 2008, 38(3): 305-310.
47	PILLAY-SMILEY N, LEACH J, LANE A, et al. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on pediatric brain tumor consortium (PBTC)-029B[J]. Cancers, 2023, 15(7): 2109.
48	FERRAZ-FILHO J R L, JOSÉ DA ROCHA A, MUNIZ M P, et al. Unidentified bright objects in neurofibromatosis type 1: conventional MRI in the follow-up and correlation of microstructural lesions on diffusion tensor images[J]. Eur J Paediatr Neurol, 2012, 16(1): 42-47.

[1]	徐文晖, 杨畅, 李瑞卿, 卞京, 李夏伊, 郑磊贞. 干扰素调节因子3促结直肠癌细胞增殖与侵袭相关探索[J]. 上海交通大学学报（医学版）, 2024, 44(3): 301-311.
[2]	郑梦奕, 毛家亮, 邹治国, 张瑞雷, 张厚, 李世光. 全身免疫炎症指数及躯体化症状评分对首发心梗PCI术后发生院内主要不良心血管事件的预测价值[J]. 上海交通大学学报（医学版）, 2024, 44(3): 334-341.
[3]	樊强, 吴广博, 赵劲博, 郑磊, 罗蒙. 肝硬化失代偿期门静脉高压症病理生理及分子机制改变的研究进展[J]. 上海交通大学学报（医学版）, 2024, 44(3): 379-384.
[4]	郭勇麟, 陈墨馨, 刘哲源, 李奕霏, 王子琦, 舒琴, 李琳. 基于人工智能技术的斜视诊疗进展[J]. 上海交通大学学报（医学版）, 2024, 44(3): 393-398.
[5]	姜允丽, 李爱求, 肖艳赏, 李田田, 胡亚晨, 张潇潇, 吴蓓蓉. 基于EMS管理模式的延续性护理在学龄前喘息性疾病儿童中的应用观察[J]. 上海交通大学学报（医学版）, 2024, 44(2): 228-236.
[6]	丁艳玲, 李杰, 袁军, 李燕. 慢性淋巴细胞白血病靶向治疗的研究进展[J]. 上海交通大学学报（医学版）, 2024, 44(2): 264-270.
[7]	朱开元, 苏瑜琛, 刘智超, 章宏, 李春光, 张杰, 李志刚. 食管鳞癌内镜黏膜下剥离术后T1b患者再治疗策略分析[J]. 上海交通大学学报（医学版）, 2024, 44(1): 116-123.
[8]	周海霞, 张靖. m⁶A甲基化修饰调控肿瘤免疫的研究进展[J]. 上海交通大学学报（医学版）, 2024, 44(1): 137-144.
[9]	李倩玉, 郭文韵, 钱逸斐, 李松玲, 朱子俊, 刘艳丰. ASGR1在肝细胞癌中的意义及机制研究[J]. 上海交通大学学报（医学版）, 2023, 43(9): 1107-1114.
[10]	吴凯敏, 麻静, 赵旭赟. 间歇性禁食联合产热脂肪活化防治小鼠肥胖作用研究[J]. 上海交通大学学报（医学版）, 2023, 43(9): 1131-1144.
[11]	朱涵菁, 殷弘凡, 尤思洁, 杨艳. 前列腺癌患者内分泌治疗相关不良反应的潜在剖面分析[J]. 上海交通大学学报（医学版）, 2023, 43(9): 1186-1193.
[12]	李郡如, 欧阳彦, 谢静远. 肠道菌群在IgA肾病发病与治疗中的作用研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(8): 1044-1048.
[13]	周婉桢, 滕银成. 非经典Wnt通路在卵巢癌中的作用与潜在治疗意义研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(8): 1056-1063.
[14]	赵艳红, 王传萍. 哮喘表型中CD4⁺ T细胞亚群的研究综述：分子机制和生物治疗选择[J]. 上海交通大学学报（医学版）, 2023, 43(8): 1064-1070.
[15]	王晓玉, 彭银辉, 马文琳, 姚博爽, 李一凡, 赵莉, 杨春霞. 新冠疫情大流行期间儿童及青少年新发焦虑症状的纵向研究[J]. 上海交通大学学报（医学版）, 2023, 43(8): 963-970.

儿童神经纤维瘤病1型颅内肿瘤性病变的治疗进展

Advances in the treatment of intracranial neoplastic lesions in children with neurofibromatosis 1

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 48

相关文章 15

编辑推荐

Metrics